OncoMatch/Clinical Trials/NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Is NCT06239194 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MDX2001 for biliary tract cancer.
Treatment: MDX2001 — This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Breast Carcinoma
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Esophageal Carcinoma
Gastric Cancer
Head and Neck Squamous Cell Carcinoma
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Prostate Cancer
Renal Cell Carcinoma
Thyroid Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Adequate hematologic, hepatic and renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute · Denver, Colorado
- Sylvester Comprehensive Cancer Center - University of Miami Health System · Miami, Florida
- Massachusetts General Hospital · Boston, Massachusetts
- Sarah Cannon Research Institute · Nashville, Tennessee
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify